The pharmacology of tacrine at N-methyl-d-aspartate receptors. 2017

Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
Institute of Physiology, Academy of Sciences of the Czech Republic v.v.i., Videnska 1083, 14220 Prague 4, Czech Republic.

The mechanism of tacrine as a precognitive drug has been considered to be complex and not fully understood. It has been reported to involve a wide spectrum of targets involving cholinergic, gabaergic, nitrinergic and glutamatergic pathways. Here, we review the effect of tacrine and its derivatives on the NMDA receptors (NMDAR) with a focus on the mechanism of action and biological consequences related to the Alzheimer's disease treatment. Our findings indicate that effect of tacrine on glutamatergic neurons is both direct and indirect. Direct NMDAR antagonistic effect is often reported by in vitro studies; however, it is achieved by high tacrine concentrations which are not likely to occur under clinical conditions. The impact on memory and behavioral testing can be ascribed to indirect effects of tacrine caused by influencing the NMDAR-mediated currents via M1 receptor activation, which leads to inhibition of Ca2+-activated potassium channels. Such inhibition prevents membrane repolarization leading to prolonged NMDAR activation and subsequently to long term potentiation. Considering these findings, we can conclude that tacrine-derivatives with dual cholinesterase and NMDARs modulating activity may represent a promising approach in the drug development for diseases associated with cognitive dysfunction, such as the Alzheimer disease.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013619 Tacrine A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tetrahydroaminoacridine,1,2,3,4-Tetrahydro-9-acridinamine,1,2,3,4-Tetrahydroaminoacridine,9-Amino-1,2,3,4-Tetrahydroacridine,Cognex,Romotal,THA,Tacrine Hydrochloride,Tenakrin
D016194 Receptors, N-Methyl-D-Aspartate A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity. N-Methyl-D-Aspartate Receptor,N-Methyl-D-Aspartate Receptors,NMDA Receptor,NMDA Receptor-Ionophore Complex,NMDA Receptors,Receptors, NMDA,N-Methylaspartate Receptors,Receptors, N-Methylaspartate,N Methyl D Aspartate Receptor,N Methyl D Aspartate Receptors,N Methylaspartate Receptors,NMDA Receptor Ionophore Complex,Receptor, N-Methyl-D-Aspartate,Receptor, NMDA,Receptors, N Methyl D Aspartate,Receptors, N Methylaspartate

Related Publications

Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
March 2016, Neuroscience letters,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
December 2006, Molecular neurobiology,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
January 1999, Neuroscience,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
July 2021, European journal of medicinal chemistry,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
October 2014, Neuropharmacology,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
August 2003, Biochemical Society transactions,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
January 1990, Advances in pharmacology (San Diego, Calif.),
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
August 1996, Neuroscience letters,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
October 1999, The Journal of pharmacology and experimental therapeutics,
Martin Horak, and Kristina Holubova, and Eugenie Nepovimova, and Jan Krusek, and Martina Kaniakova, and Jan Korabecny, and Ladislav Vyklicky, and Kamil Kuca, and Ales Stuchlik, and Jan Ricny, and Karel Vales, and Ondrej Soukup
April 1992, European journal of pharmacology,
Copied contents to your clipboard!